India, Dec. 10 -- Zydus Lifesciences on Wednesday announced the launch of Zyrifa, a biosimilar of Denosumab, used in the treatment of osteoporosis and in preventing skeletal-related complications in cancer patients.
Denosumab is a monoclonal antibody widely prescribed to improve bone health, particularly for individuals suffering from osteoporosis and those undergoing cancer treatments that increase the risk of bone deterioration.
With Zyrifa's introduction, Zydus aims to enhance accessibility to effective bone-protection therapy, supporting both osteoporosis management and skeletal care in oncology settings.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....